Cardiotoxicity associated with CTLA4 and PD1 blocking immunotherapy
Open Access
- 16 August 2016
- journal article
- research article
- Published by BMJ in Journal for ImmunoTherapy of Cancer
- Vol. 4 (1), 50
- https://doi.org/10.1186/s40425-016-0152-y
Abstract
Immune-checkpoint blocking antibodies have demonstrated objective antitumor responses in multiple tumor types including melanoma, non-small cell lung cancer (NSCLC), and renal cell cancer (RCC). In melanoma, an increase in overall survival has been demonstrated with anti-CTLA-4 and PD-1 inhibition. However, a plethora of immune-mediated adverse events has been reported with these agents. Immune-mediated cardiotoxicity induced by checkpoint inhibitors has been reported in single cases with variable presentation, including myocarditis and pericarditis. Among six clinical cancer centers with substantial experience in the administration of immune-checkpoint blocking antibodies, eight cases of immune-related cardiotoxicity after ipilimumab and/or nivolumab/pembrolizumab were identified. Diagnostic findings, treatment and follow-up are reported. A large variety of cardiotoxic events with manifestations such as heart failure, cardiomyopathy, heart block, myocardial fibrosis and myocarditis was documented. This is the largest case series to date describing cardiotoxicity of immune-checkpoint blocking antibodies. Awareness, monitoring of patients with pre-existing cardiac disorders and prompt evaluation by the treatment team is essential. Treatment including application of steroids is critical for patient safety.Keywords
This publication has 35 references indexed in Scilit:
- Late Onset Ipilimumab-Induced Pericarditis and Pericardial Effusion: A Rare but Life Threatening ComplicationCase Reports in Oncological Medicine, 2015
- Arthritis and Tenosynovitis Associated With the Anti-PD1 Antibody Pembrolizumab in Metastatic MelanomaJournal of Immunotherapy, 2015
- Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trialThe Lancet, 2014
- Pituitary Expression of CTLA-4 Mediates Hypophysitis Secondary to Administration of CTLA-4 Blocking AntibodyScience Translational Medicine, 2014
- Re-orienting the immune systemOncoImmunology, 2013
- PD-1 Protects against Inflammation and Myocyte Damage in T Cell-Mediated MyocarditisThe Journal of Immunology, 2012
- Ipilimumab-Induced Sarcoidosis in a Patient With Metastatic Melanoma Undergoing Complete RemissionJournal of Clinical Oncology, 2012
- Anti-CTLA4 Antibody–Induced Lupus NephritisNew England Journal of Medicine, 2009
- Programmed Death Ligand 1 Regulates a Critical Checkpoint for Autoimmune Myocarditis and Pneumonitis in MRL MiceThe Journal of Immunology, 2008
- Tumor Regression and Autoimmunity in Patients Treated With Cytotoxic T Lymphocyte–Associated Antigen 4 Blockade and Interleukin 2: A Phase I/II StudyAnnals of Surgical Oncology, 2005